HomeCompareGNFTF vs XYLD

GNFTF vs XYLD: Dividend Comparison 2026

GNFTF yields 19.18% · XYLD yields 11.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNFTF wins by $43.5K in total portfolio value
10 years
GNFTF
GNFTF
● Live price
19.18%
Share price
$10.43
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.4K
Annual income
$6,165.13
Full GNFTF calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
11.20%
Share price
$38.36
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.9K
Annual income
$3,351.03
Full XYLD calculator →

Portfolio growth — GNFTF vs XYLD

📍 GNFTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNFTFXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNFTF + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNFTF pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNFTF
Annual income on $10K today (after 15% tax)
$1,629.91/yr
After 10yr DRIP, annual income (after tax)
$5,240.36/yr
XYLD
Annual income on $10K today (after 15% tax)
$952.37/yr
After 10yr DRIP, annual income (after tax)
$2,848.38/yr
At 15% tax rate, GNFTF beats the other by $2,391.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNFTF + XYLD for your $10,000?

GNFTF: 50%XYLD: 50%
100% XYLD50/50100% GNFTF
Portfolio after 10yr
$47.6K
Annual income
$4,758.08/yr
Blended yield
9.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GNFTF right now

GNFTF
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
0.2
Piotroski
2/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNFTF buys
0
XYLD buys
0
No recent congressional trades found for GNFTF or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNFTFXYLD
Forward yield19.18%11.20%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$69.4K$25.9K
Annual income after 10y$6,165.13$3,351.03
Total dividends collected$38.6K$20.2K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: GNFTF vs XYLD ($10,000, DRIP)

YearGNFTF PortfolioGNFTF Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$12,618$1,917.55$10,840$1,120.44+$1.8KGNFTF
2$15,762$2,261.19$11,786$1,249.59+$4.0KGNFTF
3$19,505$2,639.91$12,854$1,397.78+$6.7KGNFTF
4$23,924$3,053.13$14,063$1,568.33+$9.9KGNFTF
5$29,098$3,499.76$15,434$1,765.19+$13.7KGNFTF
6$35,113$3,978.25$16,995$1,993.14+$18.1KGNFTF
7$42,058$4,486.56$18,777$2,257.95+$23.3KGNFTF
8$50,024$5,022.33$20,818$2,566.58+$29.2KGNFTF
9$59,109$5,582.83$23,163$2,927.50+$35.9KGNFTF
10$69,411$6,165.13$25,865$3,351.03+$43.5KGNFTF

GNFTF vs XYLD: Complete Analysis 2026

GNFTFStock

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Full GNFTF Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this GNFTF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNFTF vs SCHDGNFTF vs JEPIGNFTF vs OGNFTF vs KOGNFTF vs MAINGNFTF vs QYLDGNFTF vs JEPQGNFTF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.